Importantly, these distinct stem-states were identified in larger cohorts of pre-cisplatin and post-cisplatin treated HNSCC patients as well as in TCGA dataset, where higher SOX9 expression correlated with elevated mesenchymal properties and poor survival, compared to SOX2 expression. This evidence concerns the gene SOX9 and head and neck squamous cell carcinoma.